Company Filing History:
1 out of 54 
1 out of 10 Years Active: 2014
Title: The Innovative Mind of Se-Wan Park: Advancements in Rheumatoid Arthritis Treatment
Introduction: Se-Wan Park, located in Gyeonggi-do, South Korea, is an accomplished inventor recognized for his contributions to the pharmaceutical industry. His research focuses on developing an effective pharmaceutical composition aimed at preventing or treating rheumatoid arthritis, highlighting his commitment to improving patient care.
Latest Patents: Se-Wan Park holds a patent for a pharmaceutical composition that incorporates rebamipide as an active ingredient. This innovative formulation serves as a treatment option for rheumatoid arthritis and can be administered orally in forms such as tablets or capsules. The patent outlines a unit dosage form that safely delivers rebamipide in a range of 0.5 to 50 mg/kg, with a preferred dosage range of 0.6 to 6 mg/kg, showcasing his dedication to effective and patient-friendly medication solutions.
Career Highlights: Over the years, Se-Wan Park has made notable impacts through his work in renowned organizations. He has collaborated with the Catholic University Industry Academic Cooperation Foundation and Hanlim Pharmaceutical Co., Ltd., where he has contributed to various research and development projects aimed at advancing pharmaceutical innovation.
Collaborations: Throughout his career, Se-Wan Park has had the opportunity to work alongside esteemed colleagues such as Jun-Ki Min and Mi-La Cho. These collaborations have enabled him to enhance his research outcomes and push the boundaries of pharmaceutical advancements.
Conclusion: Se-Wan Park exemplifies the spirit of innovation in the field of pharmaceuticals, particularly in the treatment of rheumatoid arthritis. His dedication to research and development, alongside his invaluable collaborations, positions him as a significant figure in advancing therapeutic options for this challenging condition.